Cargando…

A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis

BACKGROUND: Previous works suggested that neutralizing intratumoral lactic acidosis combined with glucose deprivation may deliver an effective approach to control tumor. We did a pilot clinical investigation, including a nonrandomized (57 patients with large HCC) and a randomized controlled (20 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Chao, Ming, Wu, Hao, Jin, Kai, Li, Bin, Wu, Jianjun, Zhang, Guangqiang, Yang, Gong, Hu, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970867/
https://www.ncbi.nlm.nih.gov/pubmed/27481188
http://dx.doi.org/10.7554/eLife.15691
Descripción
Sumario:BACKGROUND: Previous works suggested that neutralizing intratumoral lactic acidosis combined with glucose deprivation may deliver an effective approach to control tumor. We did a pilot clinical investigation, including a nonrandomized (57 patients with large HCC) and a randomized controlled (20 patients with large HCC) study. METHODS: The patients were treated with transarterial chemoembolization (TACE) with or without bicarbonate local infusion into tumor. RESULTS: In the nonrandomized controlled study, geometric mean of viable tumor residues (VTR) in TACE with bicarbonate was 6.4-fold lower than that in TACE without bicarbonate (7.1% [95% CI: 4.6%–10.9%] vs 45.6% [28.9%–72.0%]; p<0.0001). This difference was recapitulated by a subsequent randomized controlled study. TACE combined with bicarbonate yielded a 100% objective response rate (ORR), whereas the ORR treated with TACE alone was 44.4% (nonrandomized) and 63.6% (randomized). The survival data suggested that bicarbonate may bring survival benefit. CONCLUSIONS: Bicarbonate markedly enhances the anticancer activity of TACE. FUNDING: Funded by National Natural Science Foundation of China. CLINICAL TRIAL NUMBER: ChiCTR-IOR-14005319.